Abeona Therapeutics (ABEO) stock: Winston Score, insiders and Congress trades

Abeona Therapeutics is a small biotech company that develops gene therapies for rare, serious skin diseases. Its main product is prademagene zamikeracel (pz-cel), a cell and gene therapy approved by the FDA in 2024 for recessive dystrophic epidermolysis bullosa (RDEB), a painful genetic condition that causes the skin to blister and tear easily. The company focuses on patients with very few or no other treatment options. Abeona makes money by selling pz-cel, marketed as Zynteglo's competitor in the rare skin disease space, directly to specialized treatment centers in the United States. With a market cap of roughly $400 million, it is a small commercial-stage company still spending heavily to build out its sales and manufacturing infrastructure, which explains the deeply negative operating margin. The key growth driver is expanding the number of treatment centers and patients receiving pz-cel, while the main risk is whether the company can reach enough patients to generate sustainable revenue before needing additional funding.